Menu Search
Equities

Diagnostic Medical Systems SA

DMS1:FRA

Diagnostic Medical Systems SA

Actions
  • Price (EUR)0.728
  • Today's Change-0.012 / -1.62%
  • Shares traded--
  • 1 Year change-19.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Diagnostic Medical Systems SA grew revenues 19.51% from 35.27m to 42.15m while net income improved from a loss of 6.82m to a smaller loss of 4.95m.
Gross margin38.00%
Net profit margin-34.17%
Operating margin-12.16%
Return on assets-30.18%
Return on equity-110.04%
Return on investment-57.32%
More ▼

Cash flow in EURView more

In 2023, Diagnostic Medical Systems SA increased its cash reserves by 8.25%, or 362.00k. Cash Flow from Financing totalled 3.48m or 8.26% of revenues. In addition the company used 1.65m for operations while cash used for investing totalled 1.48m.
Cash flow per share-0.5985
Price/Cash flow per share--
Book value per share0.6862
Tangible book value per share-0.2289
More ▼

Balance sheet in EURView more

Diagnostic Medical Systems SA has a Debt to Total Capital ratio of 59.91%, a lower figure than the previous year's 63.20%.
Current ratio1.29
Quick ratio0.6439
Total debt/total equity1.67
Total debt/total capital0.5991
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.